title: Understanding of chemoprophylaxis and concordance in inflammatory bowel disease.
abstract: OBJECTIVE
  To assess patients' understanding for the reasons for taking 5-aminosalicylic acid or ursodeoxycholic acid as chemoprophylaxis against colorectal carcinoma associated with inflammatory bowel disease (IBD).
  
  
  METHODS
  A questionnaire-based study using a 5-point opinion scale was performed. One hundred and ninety-two patients with colitis only and 74 patients with primary sclerosing cholangitis and IBD were invited to take part.
  
  
  RESULTS
  Overall response rate was 58%. Sixty-four percent of patients claimed full concordance with chemoprophylaxis for maintenance of remission. Eighty-four percent of patients considered daily concordance during remission to be very important. Seventy-five percent stated they understood the reasons for taking the drugs. However, only 50% of the patients were aware of any link of their condition to bowel cancer. Seventy-nine percent of patients felt their concordance and understanding would be improved if they were informed of the chemoprophylactic potential of the medication.
  
  
  CONCLUSIONS
  Despite good self-reported concordance, half of the patients were unaware of an association between colitis and bowel cancer. Explaining the potential chemoprophylactic benefits may enhance patients' overall concordance to 5-aminosalicylic acid and ursodeoxycholic acid and help maintain remission.
authors.affiliation: Department of Gastroenterology, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, B15 6HT, UK.
authors.forename: Adam
authors.initials: A
authors.lastname: Low
authors.forename: Melanie
authors.initials: M
authors.lastname: Love
authors.forename: Robert
authors.initials: R
authors.lastname: Walt
authors.forename: Katherine
authors.initials: K
authors.lastname: Kane
authors.forename: Bertus
authors.initials: B
authors.lastname: Eksteen
authors.forename: Jason
authors.initials: J
authors.lastname: Goh
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use*; D010349:Patient Compliance; D010353:Patient Education as Topic; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002756:Cholagogues and Choleretics; D019804:Mesalamine; D014580:Ursodeoxycholic Acid